Humanized CART19 Phase 2 Trial

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

8 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This purpose of this study is to determine the efficacy of humanized CD19 CAR  T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). You may be eligible to participate if you are between the ages of 1-29 years with CD19-expressing B-ALL that is refractory to chemotherapy, has relapsed in the bone marrow

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at oncointake [at] chop.edu or 215-425-7193.

Eligibility & Criteria

IRB #:
18-015566
Official Title:
Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T cells (huCART19) for Very High-Risk Subsets of B cell Acute Lymphoblastic Leukemia (B-ALL)
Study Phase:
Phase II
Eligible Age Range:
1 - 29 Years
Gender:
All
Study Categories:
Leader
Shannon L. Maude

Shannon L. Maude, MD, PhD